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Abstract
We first demonstrate a simple and rapid fabrication protocol of bovine serum albumin (BSA) nanoparticles (NPs), as potential drug
carriers using a microchannel flow technique with the successful encapsulation of a water-soluble kynurenic acid (KYNA) having
neuroactive property has also been performed. By comparison, the preparation of a hydrophobic α-Tocopherol (TP)-loaded
polylactide-co-glycolide 50:50 (PLGA50)-based NPs was also carried out under flow conditions. We highlight several benefits of
the flow technique over the commonly known self-assembly and nanoprecipitation processes. The average particle diameter, the size
distribution, the encapsulation efficiency (EE%) and the drug release kinetics of these different core-shell typeNPs prepared by the flow
as well as the above-mentioned classic methods were compared. The decisive role of the flow rate (FR), the relative flow rate (RFR) of
the components in the particle size of both BSA- and PLGA50-based NPs have also been verified. By utilization of the optimal flow
conditions, the average size can be decreased with ca. 15–20% and lower polydispersity index (PDI) can be also achieved. It was
confirmed that the systematic change of the RFR values resulting in the controlled size of the drug-loaded BSANPs between 120 and
140 nm, while d = 149 nm was obtained for self-assembled NPs. However, for BSA-based NPs quite similar EE% was obtained for
both methods (ca. 11–12%), but for PLGA50/TP NPs the application of flow device increased the EE% from 67.0% to 71.5%.
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Introduction
Several fabrication protocols are known in the literature for
producing serum protein and polymeric (e.g. PLA, PLGA,
chitosan, alginate etc.) nanoparticles (NPs) as potential colloi-
dal drug delivery systems (DDs) in the modern pharmaceuti-
cal researches. In case of serum albumin NPs, the commonly
used preparation protocol is the desolvation process [1], where
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a continuous dropwise addition of ethanol to an aqueous so-
lution of albumin is carried out under continuous stirring in the
absence or mainly in the presence of crosslinking agents like
glutaraldehyde [2], carbodiimides [3] or others [4], etc. By
utilizing crosslinkers, the aggregation of protein particles can
be eliminated and depending on the structure and the solubil-
ity of the encapsulated drug(s), serum albumin-based NPs in
the average diameter of ca. 80–1000 nm can be fabricated.
The main disadvantage of this technique is the demand for
the strict purification step(s), where the separation of different
serum albumin fractions is necessary, and the removal of
unreacted crosslinkers is also required. Beside the desolvation
technique, the emulsification (using nano- [5] or mainly
microemulsions [6]) is also widely used, which results in
NPs with average diameter of ~ 100–1000 nm, but the thermal
stabilization [7] of the albumin nanospheres or the application
of stabilizing agents like surfactants [8] or crosslinking mole-
cules (e.g. 2,3-butadiene or formaldehyde [8]) are indispens-
able for this technique. This process requires organic solvents
and the removal of both the surfactants and oily residues is
problematic. Moreover, the thermal gelation [9], the nano-
spray drying [10], the gamma irradiation [11], the albumin-
bound technology (nab-technology) [12] or the self-assembly
[13] techniques are also known for fabrication of different drug-
containing albumin NPs. Comparing the mentioned techniques,
we can conclude that the thermal stabilization is only suitable for
encapsulating drugmolecules that are not heat sensitive. However,
the nano spray drying is a simple and scalable technique, but it
produces larger particles in the size range of 0.5–3 μm and high
pressure is necessary for preparation of albumin NPs using nab-
technology. For the preparation of polymeric NPs, the emulsifica-
tion [1] the thermal gelation [14], the self-assembly [1] as well as
the desolvation or nanoprecipitation [15–17] techniques are also
commonly applied; the benefits and difficulties of these methods
are summarized above. Beside the mentioned well-known proto-
cols, the microfluidic technology provides an alternative strategy
for the fabrication of both polymeric and serum albumin NPs.
Reviewing the articles in the literature, it can be stated that, while
for polymers, several publications summarize the benefits of the
flow process like tunable size, structure and surface, narrow size
distribution, precisely controlled release profile as well as the pos-
sibility of the encapsulation of water-soluble and insoluble drugs
[18–21], but no articles are found relating to the fabrication of
core-shell type, drug-loaded albumin-based NPs prepared by
microfluidic technique.
In this actual work, we firstly demonstrate the preparation
possibility of BSA protein-based NPs in a simple flow system,
where the encapsulation of a hydrophilic kynurenic acid
(KYNA) having neuroactive feature [22, 23] has been also
carried out. Our previous published work [24], which clearly
summarizes the preparation of a promising nanosized BSA-
based drug delivery product containing KYNA - fabricated by
self-assembly technique - is a patented invention (Hungarian
patent, P1500356) [25]. This reason also strongly confirms the
demand of the development of a new, controllable preparation
process, that results in particles with tunable size and narrow
size distribution. The microfluidic strategy may offer an ex-
cellent opportunity for automatized large-scale pharmaceuti-
cal production. Moreover, the preparation of PLGA50
polymer-based NPs has also been carried out under flow con-
ditions, where the polymeric NPs were loaded with a hydro-
phobic tocopherol (TP) molecules and the results of the hy-
drophilic albumin- and the hydrophobic polymeric systems
were compared and interpreted. The present investigation also
aimed to compare the results obtained from this simple flow-
based and the classic preparation protocols like self-assembly
and desolvation or nanoprecipitation, therefore we explored
the effect of the preparation parameters (flow rate, relative
flow rate, pressure) on the average particle diameter, size dis-
tribution, drug loading (DL%), EE% and drug release kinetics
of the different drug-nanocarrier systems.
Experimental
Materials
Bovine serum albumin (BSA, ~66.000 Da molecular weight),
kynurenic acid (KYNA, ≥ 98%), (±)-α-Tocopherol (TP, ≥
96%), Pluronic-F127 (PLUR, ≥ 99%), poly(allylamine hydro-
chloride (PAH, Mw ~ 15.000 Da), poly(lactide-co-glycolide
acid) copolymer (PLGA50, ≥ 99% at 50:50 monomer ratio,
Mw = 30.000–60.000 Da) and sodium dihydrogen phosphate
monohydrate (NaH2PO4 × H2O, ≥ 99%) were purchased from
Sigma-Aldrich. Disodium hydrogen phosphate (Na2HPO4,
≥99%), sodium chloride (NaCl, ≥99%) and sodium hydroxide
pastilles (NaOH, ≥96%) were purchased from Molar
Chemicals Ltd. Highly purified water (MQ) was used during
the experiments obtained by deionization and filtration with a
Millipore purification apparatus (18.2 MΩ·cm at 25 °C). All
reagents and solvents used were of analytical grade.
Preparation of BSA-based NPs containing KYNA
and TP
Throughout the bulk syntheses of core-shell NPs, all the sam-
ples were prepared in phosphate buffer saline (PBS, pH =
7.40) solution at 25 °C according to the procedure published
earlier [24] with a minor modification. Firstly, 24.0 mg of
BSAwas dissolved in 8.0 mL PBS and stirred (350 rpm) until
it completely dissolved. Then, 13.82 mg of KYNAwas added
to this solution; after 2 h of stirring the 2 mL of aqueous
solution of the polyelectrolyte PAH (c = 2.01 mg/mL) was
administered to the reaction mixture (drop by drop). The same
preparation method and amounts were used for the encapsu-
lation of TP in BSA/PAH complex.
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Preparation of PLGA50-based NPs containing KYNA
and TP
The PLGA/TP and PLGA/KYNA NPs were prepared by
nanoprecipitation method [16]. 5.0 mg of PLGA50 was dis-
solved in 1.0 mL of acetone. This solution was added
dropwise (10 μL/5 s) into the 10 mL of aqueous solution of
PLUR stabilizer (c = 0.1 mg/mL) under 1000 rpm magnetic
stirring at room temperature. In case of the preparation of the
drug-loaded NPs, 1.25 mg of TP was dissolved in the acetone
phase, while the KYNA (1.25 mg) was dispersed in the aque-
ous phase, and the dispersions were further stirred (350 rpm)
for 2 days to remove the acetone by evaporation.
Preparation of BSA-and PLGA50 core-shell NPs
in microfluidic device
The microfluidic syntheses were carried out in Syrris Asia
Flow system (Syrris Ltd.) equipped with two syringe pumps
and a direct connection to the μ-mixer cell with a volume of
250 μL, and a pressure controller apparatus. After passing
through the syringe pumps, the two solutions mixing in the
μ-mixer cell and then the sample collected in defined time
intervals. The schematic representation of the preparation of
the core-shell NPs by this microfluid device is presented in
Scheme 1. The FR and the RFR were adjusted easily during
the synthesis of the drug-loaded NPs.
In case of BSA-containing core-shell NPs the same concen-
trations were used than for the self-assembly method. After
the 2 h of stirring of the BSA/KYNA solution, the PAH con-
taining solution was added to the channel 1 (v1), while the
BSA- and drug-containing solution was filled into the channel
2 (v2). For the determination of the optimal RFR, in the first
measurements the FR was kept constant (v2 = 500 μL/min)
while the aqueous PAH solution was varied in defined flow
parameter intervals (v1 = 25–150 μL/min). In a second exper-
iment series the v1:v2 ratio of the solutions was kept constant
(v1:v2 = 1:4), while the v1 and v2 values were continually in-
creased. For both preparation methods, the NPs were separat-
ed by centrifugation at 5000 rpm for 10 min and the samples
were freeze-dried (Christ Alpha 1–2 LD plus) for 24 h and
stored at −20 °C.
For PLGA-containing core-shell NPs the organic phase
(PLGA and TP in acetone) flowed in channel 1 (v1), and in
the other channel, the aqueous solution of PLUR is steamed
(v2). Firstly, the FR of the organic phase was kept constant (v1;
25 μL/min), while the aqueous phase was changed in the
range of v2 = 250–1250 μL/min. In the next step, the v1:v2
ratio of the solutions was fixed (v1:v2 = 1:10) and the FR
values were increased. During the washing step, the prepared
samples were centrifuged at 12000 rpm (15 min, 25 °C) and
the supernatant was removed; this step was repeated three
times, then the purified NPs were lyophilized.
Characterization of the prepared core-shell NPs
Dynamic light scattering (DLS) studies were performed in
HORIBA SZ-100 NanoParticle Analyzer (Retsch
Technology GmbH, Germany) at room temperature. The light
source was a diode pumped frequency doubled laser (λ =
532 nm, 10 mW) and photomultiplier tubes (PMT) were used
as the detector at 90° scattering angle. For the measurements,
the viscosity (η, mPa·s or T (K) dependent equation) of the
solvent and the refractive index of the measured particles must
be given, then the photon correlation method is used to ac-
quire the auto correlation function G2(τ) vs. scattering light
intensity I(t). To obtain the particle size distribution, the soft-
ware uses the cumulant method for calculation, then the
Scheme 1 Schematic representation of the used flow system with the pumps and the μ-mixer cell
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histogram method is applied to get the mean and the standard
deviation of the distribution function from the average of 10
separate measurement form each sample.
The transmission electron microscopy (TEM) images were
registered by using a Jeol JEM-1400plus equipment (Japan) at
120 keV accelerating voltage. For the determination of the
DL% and the EE% the absorbance spectra of the encapsulated
drugs (KYNA and TP molecules) were registered by spectro-
photometric measurements in a range of 200 nm to 600 nm
with the use of a UV-1800 (Shimadzu) double beam spectro-
photometer with a 1 cm quartz cuvette. The concentration of
the encapsulated drug (the amount of KYNA and TP) was
determined by using the classical calibration curves (Fig. S1-
S2) [16]. The characteristic absorbance band for the TP is λ =
294 nm, while for KYNA is λ = 332 nm. The well-known
DL% ad EE% values were calculated by Eqs. 1 and 2.
DL% ¼ encapsulated mass of drug
total mass of the nanoparticles
ð1Þ
EE% ¼ encapsulated mass of drug
total mass of the in synthesis
ð2Þ
In vitro release studies
The in vitro drug release experiments were carried out in PBS
(pH = 7.4, 0.9 w/w% NaCl) at 37 °C using a semipermeable
cellulose membrane (Sigma-Aldrich). For the PLGA/TP sys-
tem the poor solubility of TP was enhanced by the presence of
PLUR in the release medium (c = 1 mg/mL) according to the
studies published previously [16]. The release process was
followed for 6 h. Samples were taken every 10 min in the first
hour and then 20 min and finally once per hour. The concen-
tration of the KYNA and TP molecules in the release medium
was determined by using calibration curves (Fig. S1, S3).
Analysis of in vitro drug release data helps evaluate the release
kinetics and the proposed mechanism. Numerous mathemati-
cal models (first-order,Weibull, Korsmeyer-Peppas, etc.) have
been used to describe the release properties of the drug mole-
cules [16, 26–28]. Thementioned equations were summarized
in Suppl. Inf.
Results and discussion
Characterization of the KYNA- and TP-containing BSA-
and PLGA50 nanocarriers prepared by self-assembly
and nanoprecipitation
To compare the different preparation protocols, firstly, the
BSA- and PLGA50-based NPs have been prepared by the
c l a s s i c a l m e t h o d s l i k e s e l f - a s s e m b l y a n d
nanoprecipitation. The average diameters of the unloaded,
the KYNA- and TP-loaded NPs prepared by the classical
wet chemical techniques were determined by DLS for
both carrier systems; the representative DLS curves are
presented in Fig. 1. The average diameter of the drug-
free PLGA50 NPs is d = 124 ± 33 nm, while for polymeric
NPs containing TP and KYNA the size increased to d =
157 ± 55 nm and d = 198 ± 50 nm, respectively. However,
no articles were found for PLG50/KYNA system, but a
few publications reported PLGA50/TP NPs ranging from
ca. 85 nm to 280 nm, where the size strongly depends on
the concentration and molecular weight of the applied
polymer as well as the absence and the presence of sur-
factant stabilizer (e.g. no surfactant [29], sorbitan
monooleate (Span80) [30], sodium dodecyl sulfate
(SDS) or polyvinyl alcohol (PVA) [31]). The size of our
PLGA50/TP NPs (d = 157 ± 55 nm) stabilized by PLUR is
in good agreement with this average diameter range. For
albumin-containing drug delivery systems, the drug-free
BSA/PAH complex dispose of the smallest size (d = 107
± 34 nm), but the average diameter of the BSA/KYNA/
PAH NPs is 149 ± 44 nm. In case of the capsulation of TP
the size is increased to ca. 300 nm. Comparing the aver-
age s ize of the NPs as wel l as the solubi l i ty /
hydrophobicity of the carriers and the encapsulated mol-
ecules, i t can be stated that the serum protein-
polyelectrolyte complex is the optimal carrier for the neu-
roactive KYNA, which was also published previously
[24], while the PLGA50-PLUR polymer-surfactant forms
smaller nanocarriers containing TP molecules having hy-
drophobic nature.
To get comprehensive knowledge about the attribution of
the delivery system, both the structure and the shape of the
composites were investigated by TEM, the representative im-
ages are shown in Fig. 2.
The core-shell like structures are easily recognizable in the
optimized PLGA50/TP and BSA/KYNA/PAH composites,
suggesting the successful encapsulation of the therapeutic
agents. The average diameters of these NPs determined by
TEM images are in good correspondence with the results of
DLS studies; for pure PLGA50 = 117 ± 30 nm is obtained,
while for TP-containing PLGA50 NPs d = 148 ± 35 nm is
measured. For BSA-based NPs, d = 102 ± 40 nm and 158 ±
40 nm values were calculated before and after loading with
KYNA. In agreement with the obtained DLS results of
the PLGA50/KYNA and BSA/TP/PAH systems, the ef-
ficiency of the drug capsulation into the carriers is low
and the formation of core-shell like structures are not
recognizable based on TEM images (Fig. S4). Based on
these results, in case of the preparation of these systems
by using microfluidic device only the PLGA50/TP and
BSA/KYNA/PAH composites are studied in detail.
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Drug encapsulation in BSA/PAH and PLGA50/PLUR
NPs in flow system
Based on the experimental results of the previous chapter, the
fabrication possibilities of the BSA/KYNA/PAH and the
PLGA50/TP systems have been carried out by using a
microfluidic device. In the literature there is no reference for
the fabrication of serum-albumin NPs under flow conditions,
therefore the successful production of BSA-based core-shell
NPs was the main task of this work. However, several articles
can be found for the fabrication of PLGA50-based drug delivery
systems using microfluidic process, but no paper is available to
implement the TP encapsulation in a flow system. In the first
step, in order to find the optimal parameters for the flow-based
preparation the flow parameters (FR and RFR) of the different
channels (v1 and v2) were varied. In case of the PLGA50/TP
system the appropriate FR and RFR values together with the
average size of the formed NPs as well as the polydispersity
index (PI) determined by DLS are summarized in Table 1.
The increase of the FR of the aqueous phase (PLUR con-
taining) from 250 μL/min to 1250 μL/min results in the slight
increase in the size of the TP-free sample (from 144 nm to
167 nm). For TP-containing PLGA50 NPs only a few nm
changes were observed (148 nm to 155 nm). Using constant
RFR (1:10), but different FR (see Table 1) the average size
varies in the range of ca. 130–160 nm for both samples. The
optimal flow parameter, where the size is the smallest (d =
134 nm), is 75:750 (μL/min). The TEMmeasurements unam-
biguously confirm this observation, because the formation of
core-shell structure is clearly detectable using 75:750 μL/min
(Fig. 3b, d = 132 ± 22 nm). The TEM images of the PLGA50/
TP NPs prepared at different FR are shown in Fig. 3.
At low FR (Fig. 3a, 25:250 μL/min) the formation of the
core-shell structure is not observed, but at high flow
Fig. 2 Characteristic TEM
images of the polymer- and
protein-based NPs with and with-
out drug molecules
Fig. 1 Particle size distribution
curves of the polymer-(a), and the
protein-based NPs (b) with and
without drug molecules
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parameters (Fig. 3c, 150:1500 μl/min) the average size is in-
creased (d = 163 ± 14 nm) and the formation of only a thin
shell is observed around the higher core of the particles. For
the BSA/KYNA/PAH NPs no significant change could be
observed in the particle morphology at different FR and
RFR, but the size varied in the range of ca. 120–185 nm.
The effect of RFR in the BSA-containing carriers was also
investigated, the results are shown in Table 2. If we compare
the NPs prepared by the two technique, some morphological
differences can be observed. In case of the BSA-based nano-
composites prepared by the microfluidic technique, a more
distinct core-shell structure is observed and the polyelectrolyte
shell is thicker. The KYNA-free NPs are ca. 20% smaller than
the KYNA-loaded BSA/PAH complexes. For the BSA/
KYNA/PAH NPs, the smallest average size is obtained at
125:500 μL/min ratio (Fig. 3d, v1:v2 = 1:4, d = 121 ± 42 nm.
The effect of FR is investigated in the different channels using
this 1:4 ratio. Under this condition, the BSA/PAH composite
is very sensitive to the FR, from the use of 25:100 to
150:600 μL/min the dDLS systematically and significantly de-
creased from 147 ± 51 nm to 90 ± 24 nm in the case of
KYNA-free NPs, while from 183 ± 56 (Fig. 3e) to 129 ±
49 nm for KYNA-loaded samples, respectively.
In accordance with the DLS results of the batch- and the
flow-based fabrication processes, a significant difference in
the particle size is noticed. Compared to the flow method
prepared particles (121 ± 42 nm for BSA/KYNA/PAH and
134 ± 27 nm for PLGA/TP) to the bulk phase reaction (158
± 40 nm for BSA/KYNA/PAH, 148 ± 35 nm for PLGA/TP) it
can be stated that the flow-based preparation method results
about ca. 24 and 10% smaller particle size than the bulk phase
process, while the PI does not change significantly. Significant
Fig. 3 Characteristic TEM images of the prepared NPs using different v1:v2 flow rates. PLGA/TP NPs: a 25:250, b 75:750, c 150:1500; BSA/KYNA/
PAH NPs: d 125:500, e 25:100
Table 1 Average particle
diameter (dDLS) and
polydispersity index (PI) of
PLGA-based samples at different
flow conditions (v1, v2) deter-
mined from DLS measurements
PLGA50 (TP) PLUR RFR `TP-free TP-loaded
PLGA50 PLGA50
v1 (μL/min) v2 (μL/min) v1:v2 dDLS
a (nm) PI dDLS
a (nm) PI
25 250 1:10 144 ± 37 0.07 ± 0.03 148 ± 31 0.07 ± 0.03
25 500 1:20 147 ± 35 0.09 ± 0.04 144 ± 30 0.05 ± 0.03
25 750 1:30 153 ± 31 0.08 ± 0.06 153 ± 30 0.04 ± 0.02
25 1000 1:40 177 ± 51 0.13 ± 0.03 153 ± 38 0.04 ± 0.03
25 1250 1:50 167 ± 57 0.17 ± 0.06 155 ± 33 0.04 ± 0.02
25 250 1:10 144 ± 37 0.07 ± 0.03 148 ± 31 0.07 ± 0.03
50 500 1:10 137 ± 36 0.10 ± 0.06 141 ± 32 0.11 ± 0.03
75 750 1:10 142 ± 35 0.09 ± 0.04 134 ± 27 0.09 ± 0.04
100 1000 1:10 132 ± 33 0.10 ± 0.03 167 ± 48 0.15 ± 0.02
150 1500 1:10 159 ± 44 0.10 ± 0.06 157 ± 43 0.10 ± 0.03
a the experimental error of the peak maximum is below 2.5%
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changes in the PI are not obtained for BSA/KYNA/PAH (PI =
0.269 and 0.226 for the low- and batch-based samples, respec-
tively), but in case of PLGA50/TP NPs the PI values decrease
to ca. 0.1. It can be confirmed that the preparation of serum
albumin NPs containing a neuroactive KYNAwas successful
and by optimized concentrations as well as flow conditions a
reproducible and large-scale production of these NPs was
achieved. Besides the size, morphology and polydispersity
of the nanocarrier particles, the DL% and EE% were also
determined for the two drug carrier systems. However, in case
of BSA/PAHNPs similar values, 12.1% and 11.7% of KYNA
molecules were encapsulated using the batch- and flow prep-
aration methods (5.4% and 5.2% of DL%), respectively, but
significantly higher differences were achieved for the hy-
drophobic drug-polymer/surfactant carrier system.
Namely, 67.1% and 71.5% EE% (14.4% and 15.2%
DL%) were obtained for PLGA50/TP NPs prepared by
nanoprecipitation and under flow conditions, respectively.
According to the above presented data the encapsulation
was slightly more successful for PLGA50/TP system
using optimized flow conditions. Comparing the encapsu-
lation results with the data in the literature [29, 31], we
can confirm that, our developed flow-based fabrication
protocol has some benefits. The obtained 71.5% EE% is
significantly higher than the 45% for the 85 nm-sized
PLGA50/TP NPs published by Murugeshu et al. [29].
Their relatively low value may be due to the lack of sta-
bilizing molecules. Zigoneanu et al. published higher, 88–
95% EE% for similar PLGA50/TP system depending on
the applied SDS surfactant and PVA polymer, as stabiliz-
ing agents [31]. Effective drug carrier systems require the
use of biocompatible materials for the fabrication, which
is not satisfied by the SDS they use. We applied PLUR for
stabilization of the drug-loaded polymeric NPs, which
surfactant is commonly utilized in food production.
Release studies
After the characterization of the PLGA50/TP and BSA/
KYNA/PAH NPs, we aimed to determine the dissolution pro-
files of different drugs from the NPs. The registered dissolu-
tion curves are presented in Fig. 4.
When the flow technique is used for preparation of the
albumin-based NPs, almost 80% of the encapsulated drug is
released (Fig. 4A) from the BSA/KYNA/PAH NPs with a
diameter of ~ 120 nm, while a slower drug release can be
observed from the self-assembly-synthesized, 150 nm-sized
drug-loaded carriers; the maximum amount of the released
KYNA is about 45% (Fig. 4B) within the examined 360 min
time interval. Most probably the smaller size may facilitate the
faster release of the encapsulated KYNA, which is a beneficial
property of this composite. Previous in vitro as well as in vivo
studies [24] clearly supported the successful penetration of
Table 2 Average particle
diameter (dDLS) and
polydispersity index (PI) of BSA-
based samples at different flow
(v1, v2) conditions determined
from DLS measurements
PAH BSA (KYNA) RFR KYNA-free KYNA-loaded
BSA/PAH BSA/PAH
v1 (μL/min) v2 (μL/min) v1:v2 dDLS
a (nm) PI dDLS
a (nm) PI
25 500 1:20 114 ± 44 0.31 ± 0.03 142 ± 66 0.26 ± 0.04
50 500 1:10 93 ± 30 0.18 ± 0.06 137 ± 45 0.22 ± 0.05
75 500 1:6.7 100 ± 28 0.20 ± 0.03 139 ± 51 0.19 ± 0.03
100 500 1:5 116 ± 37 0.18 ± 0.10 122 ± 36 0.25 ± 0.03
125 500 1:4 103 ± 28 0.20 ± 0.04 121 ± 42 0.27 ± 0.04
150 500 1:3.3 117 ± 38 0.21 ± 0.02 123 ± 42 0.28 ± 0.04
25 100 1:4 147 ± 51 0.17 ± 0.03 183 ± 56 0.27 ± 0.02
50 200 1:4 150 ± 48 0.16 ± 0.03 176 ± 62 0.27 ± 0.06
75 300 1:4 139 ± 44 0.15 ± 0.03 158 ± 57 0.28 ± 0.07
100 400 1:4 130 ± 38 0.19 ± 0.03 154 ± 49 0.29 ± 0.04
125 500 1:4 103 ± 28 0.20 ± 0.04 121 ± 42 0.27 ± 0.04
150 600 1:4 90 ± 24 0.18 ± 0.04 129 ± 49 0.33 ± 0.06
a the experimental error of the peak maximum is below 2.5%
Fig. 4 Release profiles and different kinetic-models predicted (Weibull
model (A, B) and Korsmeyer-Peppas model (C, D) release curves of
KYNA (A: BSA/KYNA/PAH (flow); B: BSA/KYNA/PAH (self-
assembly) and TP (C: PLGA50/TP (flow); D: PLGA50/TP
(nanoprecipitation)) from the appropriate core-shell NPs (pH = 7.4, in
PBS)
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this albumin-based composites across the blood-brain barrier,
where the fast release is effective in contrast to the controlled
drug dissolution. In case of PLGA50/TP systems prepared by
flow technique and nanoprecipitation, in the 360 min time pe-
riod the drug availability in the release medium is 12% (Fig.
4C) and 8% (Fig. 4D) for PLGA50/TP samples, respectively.
These dissolution data are in good agreement with our previous
observations [16]. Namely, for poly(lactic acid) (PLA),
PLGA75 and PLGA65 carriers which have decreasing hydro-
phobicity in this order, 34%, 25% and 18% of the encapsulated
TP can be released from the composites, respectively. By fur-
ther reducing the hydrophobicity of the PLGA carrier, for
PLGA50 the obtained 12% and 8% values are realistic.
However, Zigoneanu et al. reported 88–95% EE% for the same
PLGA50/TPNPs, but 35% of the encapsulated TPwas released
from their composite in the first hour. Naturally, the drug release
profile depends on many parameters not only on the hydropho-
bicity but on the average particle diameter, polydispersity, den-
sity etc. [32, 33]. To gain more information about our drug-
carrier systems, we determined the release kinetics by investi-
gating the applicability of various kinetic models like Weibull,
Korsmeyer-Peppas and first-order models. The main parame-
ters are summarized in Table 3.
The measured data of the drug release fit well to the
Weibull expression, especially in case of the BSA-based sys-
tem. For the PLGA system, no significant difference can be
obtained in the release curves, but better results were detected
when fitting the 60% of the primer data points with
Korsmeyer-Peppas model. The drug release is diffusion con-
trolled, the higher diffusion dissolution index (n) values (in-
crease from 0.197 to 0.333 from nanoprecipitation to flow
method) also confirms the more homogeneous size distribu-
tion of the particles, as obtained from the DLS. The value of n
is lower than 0.42, that support the erosion of the polymer-
carrier is negligible.
Conclusion
The promising application of a simple flow-based prepara-
tion protocol for the production of colloidal drug-containing
serum albumin protein and biocompatible PLGA50
polymer core-shell NPs has been demonstrated. To the best
of our knowledge, this work is the first presenting the suc-
cessful utilization of a flow preparation strategy for the fab-
rication of serum album nanocarriers with an average diam-
eter of ca. 100 nm. Our measurements emphasize the impor-
tance of the optimization of the flow-preparation method;
well-chosen experimental parameters can be used to fine-
tune the characteristic properties of the NPs like the product
size and distribution, the DL% and EE% and the encapsu-
lated drug sustainability. Our studies highlighted that the
flow-based method results in NPs of ca. 15–20% smaller
particle size compared to the widely applied bulk-phase
methods (e.g. self-assembly or nanoprecipitation) for both
carriers. In case of the BSA/KYNA/PAH NPs prepared by
the microfluidic device the encapsulated drug is released
almost two times faster than from the bulk phase prepared
samples, which makes the use of the microfluidic device
more advantageous if rapid neuroactive drug dissolution is
required. For the PLGA/TP system, the drug sustainability
is not changed significantly by modification of the prepara-
tion methods (about 12% of the encapsulated amount re-
leased within 360 min). We can conclude from the evalua-
tion of the dissolution kinetics, that for the PLGA/TP NPs
the most decisive process is the diffusion, while for the
BSA/KYNA/PAH nanocarrier, besides the diffusion, the
erosion of the carrier system also plays an important role
in the release of encapsulated KYNA. Owing to the above-
mentioned features, after adjusting the parameters, the flow-
based preparation method may offer an alternative opportu-
nity for a reproducible, tunable and automatized large-scale
pharmaceutical production.
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Table 3 Parameters of the dissolution of TP and KYNA derived from the fitting of the release curves by several kinetic models
Sample First-order Korsmeyer-Peppas Weibull
Model k (min−1) R2 km (min
-n) n R2 a b R2
BSA/KYNA/PAH (flow) 0.0229 0.9708 0.217 0.346 0.9843 8.201 0.707 0.9998
BSA/KYNA/PAH (self-assembly) 0.0137 0.9884 0.068 0.527 0.9973 27.456 0.793 0.9954
PLGA50/TP (flow) 0.0088 0.9497 0.168 0.333 0.9934 8.367 0.545 0.9882
PLGA50/TP (nanoprecipitation) 0.0115 0.9189 0.320 0.197 0.9793 4.164 0.430 0.9728
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